Incannex Healthcare Acquiring Apirx (IXHL)


Incannex was already in a position to be a global leader in medical cannabis, psychedelic and mixed therapy treatments before news of them Acquiring Apirx and their suite of 19 granted patents plus 23 patents pending, 22 clinicals and their r and d team. With this deal, Incannex will now have an accessible market of over $520 billion dollars. Stock rose to $96 this month and then crashed because of massive profit taking following good news. It dipped to $10.70 Friday before ending the day at $11.14. Currently there are under 50m shares outstanding in this company (48.8m I think). I am invested and am going to hold long on this one because I believe once the small sellers are out of the way and the float of shares is held by mature investors, this will be a great long term hold. Link for acquisition info here:

Incannex to Acquire Apirx


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *